Biotech News
@FierceBiotech: 2013 Biotech IPOs: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech
@JohnCFierce: Deborah Dunsire makes quick leap from Millennium to fast-growing EnVivo. News | Follow @JohnCFierce
@RyanMFierce: Alnylam Pharma spotlights more upbeat human data or gene-silencing drugs. Story | Follow @RyanMFierce
@EmilyMFierce: Anti-leukemia compound could also treat common breast cancers. Story | Follow @EmilyMFierce
> Shares of Celgene ($CELG) shot up this morning after the company reported that Revlimid produced promising data in a study for multiple myeloma. And now it's preparing to file for an expanded approval of the therapy. Story
> Denmark's ALK (OMX: ALK.B) says it reaped positive data from the second of two pivotal Phase III trials of its new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases. Release
> Sorrento Therapeutics and researchers at Israel's Ben-Gurion University of the Negev are partnering to develop anti-hepatitis C antibodies. Report
Medical Device News
@FierceMedDev: ICYM this week's M&A feature - Blockbusters and bloodlettings: A look at 2013's hot start. Special report | Follow @FierceMedDev
@MarkHFierce: Only a few weeks left to nominate a company for this year's FMD Fierce 15. Submit your nomination | Follow @MarkHFierce
@DamianFierce: Device outfit CVRx has raised $29.6M in a round led by NEA and J&J. Article | Follow @DamianFierce
> Report: Baxter's $4B bid for Gambro to win EU approval. More
> Stentys' self-apposing cardiac stent gains expanded CE mark indications. Item
> VisionCare discloses CMS coverage plan for implantable miniature telescope. Story
> Myriad targets Gene By Gene in second BRCA patent suit. Report
Pharma News
@FiercePharma: Pharma, FDA still lag in post-marketing safety studies. Getting better, but large % unfinished--or not begun. Yesterday's story | Follow @FiercePharma
@CarlyHFierce: NICE says 'no' to Celgene's Revlimid. Article | Follow @CarlyHFierce
> U.K. recalls 16 Wockhardt drugs, bans products from Indian plant. Report
> New problems for GSK in China as authorities say GSK employees confess to bribery. News
> Vivus hooks up with Menarini to hawk ED pill Spedra in $121M deal. More
Pharma Manufacturing News
@EricPFierce: BioPlan says China, India losing luster for outsourced biopharmaceutical manufacturing. More | Follow @EricPFierce
> Wockhardt faces 2nd import alert. Report
> Sanofi's ImmuCyst available in next year, Alliance Pharma says. More
> Pfizer to invest $130M in 2 plants in Ireland. News
> Contract manufacturer Piramal also into development, cellphones. Story
Vaccines News
> Manufacturers prepare for resurgence of H7N9. News
> Robot eases kids' vaccination distress in study. More
> Novartis inks typhoid vax licensing deal with Biological E. Story
> U.K. mumps outbreak linked to waning MMR protection. Report
And Finally… A new study finds that men with high concentrations of omega-3 fish oil in their blood suffered a significantly higher risk of prostate cancer, despite a range of earlier studies that found it has a tonic effect on people's health. Story